miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury
Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially...
Gespeichert in:
Veröffentlicht in: | Biomedicine & pharmacotherapy 2019-04, Vol.112, p.108664-108664, Article 108664 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 108664 |
---|---|
container_issue | |
container_start_page | 108664 |
container_title | Biomedicine & pharmacotherapy |
container_volume | 112 |
creator | Yang, Yuan Yang, Feng Yu, Xinqiao Wang, Beibei Yang, Yang Zhou, Xiaoyu Cheng, Rui Xia, Shiwen Zhou, Xiaoguang |
description | Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially focusing on Toll-like receptor 4 (TLR4) and NF-kB signaling pathway as well as NOD-like receptor protein 3 (NLRP3) inflammasome activation. We established in vivo and in vitro model of ALI using LPS and demonstrated that miR-16 expression was down-regulated in lung tissue as well as A549 cells after 8 h of LPS treatment. Furthermore, when miR-16 levels in lung tissues were up-regulated by miR-16 agomir, it was confirmed that the mRNA and protein levels of NF-κB, NLRP3 inflammasome, and inflammatory factors were decreased by the miR-16 by directly targeting TLR4. We also treated A549 cells with miR-16 mimics and anti-miR-16 to confirm the results. Overall, our experiments showed that miR-16 protects against acute lung injury in mice by regulating the TLR4/ NF-κB pathway and attenuating inflammatory response. This work suggests a potential novel therapeutic approach to combat ALI. |
doi_str_mv | 10.1016/j.biopha.2019.108664 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2184155107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0753332218377850</els_id><sourcerecordid>2184155107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-34973ed5ca2224c8449b005777b88df5d56ab0c05c92cf543682b778044d10d73</originalsourceid><addsrcrecordid>eNp9kEtLxDAQx4Mouj6-gUiPXrpOXk16EUR8waKy6FFCmqaapY81SYX99mapevQ0ZPj9ZyY_hE4xzDHg4mI1r9yw_tBzArhMLVkUbAfNcMkhLwDELpqB4DSnlJADdBjCCgB4QeU-OqAgJCspn6G3zi1zXGSu_3CViyF7XCyfaXo2re46HYbOZtpE96WjG_qs2mS189bEdpNF7d9tdP179rJYshRJ4Bht1o6p5frV6DfHaK_RbbAnP_UIvd7evFzf54unu4frq0VuGMiYU1YKamtuNCGEGclYWaVbhRCVlHXDa17oCgxwUxLTcEYLSSohJDBWY6gFPULn09y1Hz5HG6LqXDC2bXVvhzEogiXDnGPYomxCjR9C8LZRa-867TcKg9qKVSs1iVVbsWoSm2JnPxvGqrP1X-jXZAIuJ8Cmf34561UwzvbGTr5UPbj_N3wDxauJog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2184155107</pqid></control><display><type>article</type><title>miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Yang, Yuan ; Yang, Feng ; Yu, Xinqiao ; Wang, Beibei ; Yang, Yang ; Zhou, Xiaoyu ; Cheng, Rui ; Xia, Shiwen ; Zhou, Xiaoguang</creator><creatorcontrib>Yang, Yuan ; Yang, Feng ; Yu, Xinqiao ; Wang, Beibei ; Yang, Yang ; Zhou, Xiaoyu ; Cheng, Rui ; Xia, Shiwen ; Zhou, Xiaoguang</creatorcontrib><description>Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially focusing on Toll-like receptor 4 (TLR4) and NF-kB signaling pathway as well as NOD-like receptor protein 3 (NLRP3) inflammasome activation. We established in vivo and in vitro model of ALI using LPS and demonstrated that miR-16 expression was down-regulated in lung tissue as well as A549 cells after 8 h of LPS treatment. Furthermore, when miR-16 levels in lung tissues were up-regulated by miR-16 agomir, it was confirmed that the mRNA and protein levels of NF-κB, NLRP3 inflammasome, and inflammatory factors were decreased by the miR-16 by directly targeting TLR4. We also treated A549 cells with miR-16 mimics and anti-miR-16 to confirm the results. Overall, our experiments showed that miR-16 protects against acute lung injury in mice by regulating the TLR4/ NF-κB pathway and attenuating inflammatory response. This work suggests a potential novel therapeutic approach to combat ALI.</description><identifier>ISSN: 0753-3322</identifier><identifier>EISSN: 1950-6007</identifier><identifier>DOI: 10.1016/j.biopha.2019.108664</identifier><identifier>PMID: 30784935</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Acute lung injury (ALI) ; Mice ; MicroRNA-16 ; NLRP3 inflammasome ; TLR4</subject><ispartof>Biomedicine & pharmacotherapy, 2019-04, Vol.112, p.108664-108664, Article 108664</ispartof><rights>2019</rights><rights>Copyright © 2019. Published by Elsevier Masson SAS.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-34973ed5ca2224c8449b005777b88df5d56ab0c05c92cf543682b778044d10d73</citedby><cites>FETCH-LOGICAL-c408t-34973ed5ca2224c8449b005777b88df5d56ab0c05c92cf543682b778044d10d73</cites><orcidid>0000-0002-0903-5627</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0753332218377850$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30784935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Yuan</creatorcontrib><creatorcontrib>Yang, Feng</creatorcontrib><creatorcontrib>Yu, Xinqiao</creatorcontrib><creatorcontrib>Wang, Beibei</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Zhou, Xiaoyu</creatorcontrib><creatorcontrib>Cheng, Rui</creatorcontrib><creatorcontrib>Xia, Shiwen</creatorcontrib><creatorcontrib>Zhou, Xiaoguang</creatorcontrib><title>miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury</title><title>Biomedicine & pharmacotherapy</title><addtitle>Biomed Pharmacother</addtitle><description>Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially focusing on Toll-like receptor 4 (TLR4) and NF-kB signaling pathway as well as NOD-like receptor protein 3 (NLRP3) inflammasome activation. We established in vivo and in vitro model of ALI using LPS and demonstrated that miR-16 expression was down-regulated in lung tissue as well as A549 cells after 8 h of LPS treatment. Furthermore, when miR-16 levels in lung tissues were up-regulated by miR-16 agomir, it was confirmed that the mRNA and protein levels of NF-κB, NLRP3 inflammasome, and inflammatory factors were decreased by the miR-16 by directly targeting TLR4. We also treated A549 cells with miR-16 mimics and anti-miR-16 to confirm the results. Overall, our experiments showed that miR-16 protects against acute lung injury in mice by regulating the TLR4/ NF-κB pathway and attenuating inflammatory response. This work suggests a potential novel therapeutic approach to combat ALI.</description><subject>Acute lung injury (ALI)</subject><subject>Mice</subject><subject>MicroRNA-16</subject><subject>NLRP3 inflammasome</subject><subject>TLR4</subject><issn>0753-3322</issn><issn>1950-6007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLxDAQx4Mouj6-gUiPXrpOXk16EUR8waKy6FFCmqaapY81SYX99mapevQ0ZPj9ZyY_hE4xzDHg4mI1r9yw_tBzArhMLVkUbAfNcMkhLwDELpqB4DSnlJADdBjCCgB4QeU-OqAgJCspn6G3zi1zXGSu_3CViyF7XCyfaXo2re46HYbOZtpE96WjG_qs2mS189bEdpNF7d9tdP179rJYshRJ4Bht1o6p5frV6DfHaK_RbbAnP_UIvd7evFzf54unu4frq0VuGMiYU1YKamtuNCGEGclYWaVbhRCVlHXDa17oCgxwUxLTcEYLSSohJDBWY6gFPULn09y1Hz5HG6LqXDC2bXVvhzEogiXDnGPYomxCjR9C8LZRa-867TcKg9qKVSs1iVVbsWoSm2JnPxvGqrP1X-jXZAIuJ8Cmf34561UwzvbGTr5UPbj_N3wDxauJog</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Yang, Yuan</creator><creator>Yang, Feng</creator><creator>Yu, Xinqiao</creator><creator>Wang, Beibei</creator><creator>Yang, Yang</creator><creator>Zhou, Xiaoyu</creator><creator>Cheng, Rui</creator><creator>Xia, Shiwen</creator><creator>Zhou, Xiaoguang</creator><general>Elsevier Masson SAS</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0903-5627</orcidid></search><sort><creationdate>20190401</creationdate><title>miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury</title><author>Yang, Yuan ; Yang, Feng ; Yu, Xinqiao ; Wang, Beibei ; Yang, Yang ; Zhou, Xiaoyu ; Cheng, Rui ; Xia, Shiwen ; Zhou, Xiaoguang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-34973ed5ca2224c8449b005777b88df5d56ab0c05c92cf543682b778044d10d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acute lung injury (ALI)</topic><topic>Mice</topic><topic>MicroRNA-16</topic><topic>NLRP3 inflammasome</topic><topic>TLR4</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Yuan</creatorcontrib><creatorcontrib>Yang, Feng</creatorcontrib><creatorcontrib>Yu, Xinqiao</creatorcontrib><creatorcontrib>Wang, Beibei</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Zhou, Xiaoyu</creatorcontrib><creatorcontrib>Cheng, Rui</creatorcontrib><creatorcontrib>Xia, Shiwen</creatorcontrib><creatorcontrib>Zhou, Xiaoguang</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biomedicine & pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Yuan</au><au>Yang, Feng</au><au>Yu, Xinqiao</au><au>Wang, Beibei</au><au>Yang, Yang</au><au>Zhou, Xiaoyu</au><au>Cheng, Rui</au><au>Xia, Shiwen</au><au>Zhou, Xiaoguang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury</atitle><jtitle>Biomedicine & pharmacotherapy</jtitle><addtitle>Biomed Pharmacother</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>112</volume><spage>108664</spage><epage>108664</epage><pages>108664-108664</pages><artnum>108664</artnum><issn>0753-3322</issn><eissn>1950-6007</eissn><abstract>Acute lung injury (ALI) is the leading cause of human death, and it is widely accepted that the runaway inflammation is an important risk for the development of ALI. In the present study, we aimed to investigate the effect of miR-16 on lipopolysaccharide-induced acute lung injury in mice, especially focusing on Toll-like receptor 4 (TLR4) and NF-kB signaling pathway as well as NOD-like receptor protein 3 (NLRP3) inflammasome activation. We established in vivo and in vitro model of ALI using LPS and demonstrated that miR-16 expression was down-regulated in lung tissue as well as A549 cells after 8 h of LPS treatment. Furthermore, when miR-16 levels in lung tissues were up-regulated by miR-16 agomir, it was confirmed that the mRNA and protein levels of NF-κB, NLRP3 inflammasome, and inflammatory factors were decreased by the miR-16 by directly targeting TLR4. We also treated A549 cells with miR-16 mimics and anti-miR-16 to confirm the results. Overall, our experiments showed that miR-16 protects against acute lung injury in mice by regulating the TLR4/ NF-κB pathway and attenuating inflammatory response. This work suggests a potential novel therapeutic approach to combat ALI.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>30784935</pmid><doi>10.1016/j.biopha.2019.108664</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0903-5627</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0753-3322 |
ispartof | Biomedicine & pharmacotherapy, 2019-04, Vol.112, p.108664-108664, Article 108664 |
issn | 0753-3322 1950-6007 |
language | eng |
recordid | cdi_proquest_miscellaneous_2184155107 |
source | Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Acute lung injury (ALI) Mice MicroRNA-16 NLRP3 inflammasome TLR4 |
title | miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T11%3A38%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=miR-16%20inhibits%20NLRP3%20inflammasome%20activation%20by%20directly%20targeting%20TLR4%20in%20acute%20lung%20injury&rft.jtitle=Biomedicine%20&%20pharmacotherapy&rft.au=Yang,%20Yuan&rft.date=2019-04-01&rft.volume=112&rft.spage=108664&rft.epage=108664&rft.pages=108664-108664&rft.artnum=108664&rft.issn=0753-3322&rft.eissn=1950-6007&rft_id=info:doi/10.1016/j.biopha.2019.108664&rft_dat=%3Cproquest_cross%3E2184155107%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2184155107&rft_id=info:pmid/30784935&rft_els_id=S0753332218377850&rfr_iscdi=true |